Important Safety Information & Disclaimer
Medication options. AvataCore is a marketing and patient-acquisition platform that connects you with independently licensed medical providers. Your provider — not AvataCore — decides whether a prescription is appropriate for you, and which medication to prescribe. Depending on your evaluation, this may include either of the following:
- A compounded GLP-1 medication. Our primary program connects you with state-licensed sterile compounding pharmacies that prepare and ship compounded semaglutide or tirzepatide. Compounded medications are not FDA-approved and have not been evaluated by the FDA for safety, effectiveness, or quality. Compounded products are not generics and are not equivalent to branded medications.
- A prescription for an FDA-approved branded medication (such as Ozempic®, Wegovy®, Zepbound®, or Mounjaro®). AvataCore does not sell, dispense, or ship any branded medication. If your provider writes a branded prescription, you are responsible for filling it at the pharmacy of your choice and for any associated cost.
No guarantees. Individual results vary. Weight loss is influenced by many factors — including diet, physical activity, sleep, medical history, and individual biology — and outcomes are never guaranteed. Information on this page is for educational purposes only and is not medical advice. Talk to a qualified healthcare professional before starting, stopping, or changing any medication or weight-management program.
Subscription & billing. Plans start at $149 for the first month (compounded semaglutide injection or oral tablets) or $199 for the first month (compounded tirzepatide injection). Your subscription automatically renews each month at the standard plan rate — $299/month for semaglutide (injection or oral) or $399/month for tirzepatide — and continues until you cancel. There is no long-term commitment. You can cancel anytime from your patient portal or by emailing support@avatacore.com; cancellation before your next billing date prevents further charges. See our Refund Policy and Terms of Service for full details.
Eligibility & availability. Treatment is not appropriate for everyone, and not all medications are available in every state. Availability and pricing may change. You may be required to complete additional evaluations or labs before a provider can prescribe.
Ozempic®, Wegovy®, Zepbound®, and Mounjaro® are registered trademarks of their respective owners. AvataCore is not affiliated with, endorsed by, or sponsored by Novo Nordisk A/S or Eli Lilly and Company.
© 2026 AvataCore LLC. All rights reserved.
BOXED WARNING — Risk of Thyroid C-Cell Tumors
Compounded semaglutide/tirzepatide carries the same boxed warning as FDA-approved formulations. Contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
See full Safety Information before starting therapy.
BOXED WARNING — Risk of Thyroid C-Cell Tumors
Compounded semaglutide/tirzepatide carries the same boxed warning as FDA-approved formulations. Contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
See full Safety Information before starting therapy.
